Two major studies are looking at moving sacituzumab govitecan earlier for metastatic triple-negative breast cancer.

A new antibody‑drug conjugate nearly doubles survival and extends overall survival in advanced triple‑negative breast cancer, offering a more precise first‑line.

Triple negative breast cancer is one of the most difficult kinds of breast cancer to treat, it grows fast and historically ...

AstraZeneca and Gilead have won approval for treatments of an advanced form of the disease.

Sacituzumab govitecan approved alone or in combination for first-line treatment ...

Regulatory labeling stratifies use by PD-L1 status: monotherapy for PD-L1–negative/checkpoint-ineligible disease and combination with pembrolizumab (or Qlex) for PD ...

The robot was cleared by the FDA a few months ago to perform the delicate surgery that avoids skin and preserves the nipple.

Triple-negative breast cancer (TNBC) is aggressive and hard to treat. But the role of fat tissue in how the cancer spreads ...

Datroway ® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple ...

Datroway significantly improves overall and progression-free survival in metastatic triple-negative breast cancer patients ineligible for immunotherapy. TROPION-Breast02 trial results highlight ...

June 2026Datroway recommended for approval in the EU by CHMP as 1st-line treatment for patients with metastatic triple-negative breast cancer who are not candidates for immunotherapy Recommendation ...

When Chase Johnson was 31, her dog began acting strange. He was anxious, wouldn't leave her side and, one day, pushed his nose into the side of her breast. Johnson felt a hard lump. "I wasn't someone ...